海正药业(600267.SH)：HS387片获得美国FDA新药临床试验批准通知

Core Viewpoint - The company, Haizheng Pharmaceutical, has received approval from the U.S. FDA for its clinical trial application for the drug HS387, which is a selective KIF18A inhibitor aimed at treating advanced solid tumors such as high-grade serous ovarian cancer and non-small cell lung cancer [1] Group 1 - The company announced the approval of its clinical trial application for HS387 by the U.S. FDA [1] - HS387 is developed in-house and targets advanced solid tumors [1] - The drug is specifically intended for high-grade serous ovarian cancer and non-small cell lung cancer [1]